Richard H Gregory

US Patent:

6358507, Mar 19, 2002

Filed:

Oct 12, 1999

Appl. No.:

09/416673

Inventors:

Johanne Kaplan - Sherborn MA
Donna Armentano - Belmont MA
Richard J. Gregory - Westford MA

Assignee:

Genzyme Corporation - Framingham MA

International Classification:

A61K 4800

US Classification:

424 932, 424 936, 4353201, 435 691, 435455, 435456, 435325, 435366, 435 911, 435 914, 435 9141, 435 9142, 435371

Abstract:

The present invention relates to transgene expression systems, related compositions comprising the transgene expression systems, and methods of making and using them. Preferred systems employ an adenovirus transgene expression vector comprising DNA encoding a transgene which codes for a desired product operably linked to expression control sequence, and at least a portion of the adenovirus E3 region and certain portions of the E4 region. The E4 portions comprise the open reading frame sequence known as E40RF3 and at least one other portion of E4. Preferably the E4 portion of the vector (or âE4 cassetteâ) includes E40RF3 and at least one other portion selected from E40RF4, E40RF6/7 and E40RF3/4. The invention has a number of important features including improving persistency of transgene expression in a desired host cell. The transgene expression systems of the present invention are useful for a variety of applications including providing persistent cellular expression of the transgene in vitro and in vivo.

US Patent:

6485720, Nov 26, 2002

Filed:

Aug 8, 2001

Appl. No.:

09/924925

Inventors:

Johanne Kaplan - Sherborn MA
Donna Armentano - Belmont MA
Richard J. Gregory - Westford MA

Assignee:

Genzyme Corporation - Cambridge MA

International Classification:

A61K 4800

US Classification:

424 932, 424 931, 424 936, 4353201, 435455, 435456, 435457, 435 691, 435325, 435366

Abstract:

The present invention relates to transgene expression systems, related compositions comprising the transgene expression systems, and methods of making and using them. Preferred systems employ an adenovirus transgene expression vector comprising DNA encoding a transgene which codes for a desired product operably linked to expression control sequence, and at least a portion of the adenovirus E3 region and certain portions of the E4 region. The E4 portions comprise the open reading frame sequence known as E4ORF3 and at least one other portion of E4. Preferably the E4 portion of the vector (or âE4 cassetteâ) includes E4ORF3 and at least one other portion selected from E4ORF4, E4ORF6/7 and E4ORF3/4. The invention has a number of important features including improving persistency of transgene expression in a desired host cell. The transgene expression systems of the present invention are useful for a variety of applications including providing persistent cellular expression of the transgene in vitro and in vivo.

US Patent:

8283331, Oct 9, 2012

Filed:

Oct 8, 2008

Appl. No.:

12/682149

Inventors:

Richard I Gregory - Brookline MA, US
George Q Daley - Weston MA, US
Srinivas R Viswanathan - Brookline MA, US

Assignee:

Children's Medical Center Corporation - Boston MA

International Classification:

C12N 15/11

US Classification:

514 44A

Abstract:

The present invention relates generally to methods to regulate microRNA (miRNA) biogenesis, in particular the regulation of the processing of pri-miRNA to mature miRNA by Lin-28 and/or variants such as Lin28B. In particular, the present invention relates to methods and compositions comprising at least one agent which inhibits Lin-28 function or activity and/or expression to increase the processing of pri-mRNA to mature miRNA. More specifically, one aspect of the invention is directed to treating and/or preventing cancer in a subject by administering an agent that inhibits Lin-28 activity or expression to a subject, preferably a human subject.

US Patent:

58770119, Mar 2, 1999

Filed:

Nov 20, 1996

Appl. No.:

8/752760

Inventors:

Donna Armentano - Belmont MA
Richard J. Gregory - Westford MA
Alan E. Smith - Dover MA

Assignee:

Genzyme Corporation - Framingham MA

International Classification:

C12N 1586

US Classification:

4353201

Abstract:

A chimeric adenoviral vector is provided that comprises nucleotide sequence of a first adenovirus, wherein at least one gene of said first adenovirus encoding a protein that facilitates binding of said vector to a target mammalian cell, or internalization thereof within said cell, is replaced by the corresponding gene from a second adenovirus belonging to subgroup D, said vector further comprising a transgene operably linked to a eucaryotic promoter to allow for expression therefrom in a mammalian cell. Additionally, a method of delivering transgenes to target mammalian cells, particularly airway epithelial cells, is provided.

US Patent:

59812753, Nov 9, 1999

Filed:

Apr 14, 1997

Appl. No.:

8/839552

Inventors:

Donna Armentano - Belmont MA
John Marshall - Hopedale MA
Nelson S. Yew - West Upton MA
Seng H. Cheng - Wellesley MA
Richard J. Gregory - Westford MA

Assignee:

Genzyme Corporation - Cambridge MA

International Classification:

C12N 1500

US Classification:

4353201

Abstract:

The invention is directed to a transgene expression system comprising a transcription unit which contains a transgene operably linked to expression control sequences, preferably the CMV promoter, and which is delivered simultaneously with all or part of the adenovirus E4 genomic region to a cell in order to facilitate persistent expression of the transgene. The components of the transgene expression system can be delivered by vectors including plasmids and/or viruses and may be complexed with cationic amphiphiles to facilitate entry into a cell. The invention is also directed to methods for the production of the transgene expression system. The invention is further directed to compositions that contain the transgene expression system and to methods for the use of such compositions to deliver transgenes encoding biologically active proteins to cells.

US Patent:

61000868, Aug 8, 2000

Filed:

Apr 14, 1997

Appl. No.:

8/839679

Inventors:

Johanne Kaplan - Sherborn MA
Donna Armentano - Belmont MA
Richard J. Gregory - Westford MA

Assignee:

Genzyme Corporation - Cambridge MA

International Classification:

C12N 1586
C07J 900

US Classification:

4353201

Abstract:

The present invention relates to transgene expression systems, related pharmaceutical compositions, and methods of making and using them. Preferred systems employ an adenovirus transgene expression vector comprising DNA sequence encoding a transgene which codes for a desired product, expressibly contained within an adenovirus vector containing at least a portion of the E3 region and certain portions of the E4 region. The E4 portions comprise the open reading frame sequence known as E4ORF3 and at least one other portion of E4. Preferably the E4 portion of the vector (or "E4 cassette") includes E4ORF3 and at least one other portion selected from E4ORF4, E4ORF6/7 and E4ORF3/4. The invention has a number of important features including improving persistency of transgene expression in a desired host cell. The transgene expression systems of the present invention are useful for a variety of applications including providing persistent cellular expression of the transgene in vitro and in vivo.

US Patent:

20220195026, Jun 23, 2022

Filed:

Dec 23, 2021

Appl. No.:

17/561510

Inventors:

- Paris, FR
Kevin Brower - Holliston MA, US
Patrick Finn - Franklin MA, US
Richard C. Gregory - Framingham MA, US
Rao Koduri - Shrewsbury MA, US
Feng Liu - San Diego CA, US
Natalia Malkova - Needham MA, US
Parminder Mankoo - Foster City CA, US
Jack R. Pollard - Acton MA, US
Huawei Qiu - Westborough MA, US
Joachim Theilhaber - Cambridge MA, US
Christopher Winter - Swampscott MA, US
Marcella Yu - Fremont CA, US

Assignee:

SANOFI - Paris

International Classification:

C07K 16/22
A61P 35/00
C07K 16/28
C07K 16/30
C07K 16/32

Abstract:

The invention provides an improved pan-TGF-β antibody for treatment of conditions that are mediated by TGF-β, including autoimmune diseases, fibrotic conditions, and cancers. Also provided are methods and uses of the antibody in conjunction with other immunomodulatory agents such as an anti-PD-1 antibody.

US Patent:

20230018989, Jan 19, 2023

Filed:

Jul 2, 2020

Appl. No.:

17/624117

Inventors:

- Boston MA, US
Richard I. Gregory - Brookline MA, US

Assignee:

Children's Medical Center Corporation - Boston MA

International Classification:

C07K 16/40
C12N 15/113
A61K 38/45
A61K 38/17
C07K 16/18

Abstract:

Provided herein are method of treating cancer using agents that inhibit the interaction between Methyltransferase like 3 (METTL3) and Eukaryotic Translation Initiation Factor 3 Subunit H (EIF3h), and optionally agents that inhibit Bromodomain-containing protein 4 (BRD4). The present disclosure demonstrates the topology of individual polyribosomes with single METTL3 foci found in close proximity to 5′ cap-binding proteins, revealing a previously unknown direct physical and functional interaction between METTL3 and the eukaryotic translation initiation factor 3 subunit h (eIF3h).